Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Hexal_AG
gptkb:Eon_Labs gptkb:Sandoz_Canada_Inc. |
| gptkbp:awards |
various industry awards
|
| gptkbp:clinicalTrials |
ongoing
|
| gptkbp:communityInvolvement |
health fairs
health education programs disaster response efforts partnerships with NGOs support for local economies |
| gptkbp:corporateSocialResponsibility |
community engagement
education initiatives disaster relief employee volunteering healthcare_access |
| gptkbp:financialPerformance |
investment in R&D
consistent profitability strong revenue growth dividend payments to shareholders market leader in generics |
| gptkbp:focus |
affordable medicines
|
| gptkbp:founded |
1986
|
| gptkbp:globalPresence |
Richard_Francis
|
| gptkbp:headquarters |
gptkb:Holzkirchen,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sandoz GmbH
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:innovation |
supply chain optimization
digital health solutions patient-centric solutions focus on biosimilars focus on generics |
| gptkbp:market |
over 160 countries
|
| gptkbp:numberOfEmployees |
approximately 10,000
|
| gptkbp:operatesIn |
global market
|
| gptkbp:parentCompany |
Novartis
|
| gptkbp:partnerships |
various healthcare organizations
|
| gptkbp:productLine |
diabetes
oncology antibiotics central nervous system dermatology hormonal therapies pain management gastroenterology cardiovascular respiratory |
| gptkbp:products |
generic drugs
biosimilars |
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA |
| gptkbp:researchAndDevelopment |
biopharmaceuticals
|
| gptkbp:subsidiary |
Novartis AG
|
| gptkbp:sustainabilityInitiatives |
social responsibility
environmental responsibility economic responsibility |
| gptkbp:website |
www.sandoz.com
|